Real-Time Single-Cell Analysis of NK Cell Cytotoxicity Using Droplet-Based Microfluidics for Cancer Immunotherapy

Tech ID
25-053
Inventors
Tohid Didar
Ali Ashkar
Fatemeh L. Vahedi
Rana S. Ozcan
Patent Status
US Provisional Patent Application filed
Stage of Research
Proof of concept available
Contact
Rimika Sachdeva
Business Development Officer
Abstract
Effective cancer immunotherapy hinges on a precise understanding of immune cell functionality and their dynamic interactions with tumor targets. There is a need for a non-destructive method to functionally phenotype immune cells and measure their interactions with targets in real-time [1]. The current experimental paradigms track individual cells functionally or measure genetic/protein levels of cell populations, which may not accurately represent the physiological states of cells [1].
Researchers at McMaster University have developed a novel method and system for the comparative analysis of the cytotoxic functions of different Natural Killer (NK) cell phenotypes using droplet-based microfluidics. This approach enables the encapsulation and real-time observation of NK cells and K562, the standard human myelogenous leukemia cell line, cancer cells within microfluidic droplets, facilitating detailed single-cell analysis of their interactions and cytotoxic activities.
Applications
- Precise and real-time monitoring of NK cell interactions with cancer cells with video and photo capturing.
- Can select optimal NK cell populations for personalized immunotherapy
Advantages
- Use of droplet-based microfluidics to directly compare peripheral blood and expanded NK cells with their versions cultured in ascites tumor microenvironment.
- Ability to change the ratio of trapped NK and cancer cells within each single droplet.
- Using transfected fluorescence-labelled K562 cells, colour cell differentiation, enhances monitoring reliability and simplifies tracking.
References:
- Maffuid K, Cao Y. Decoding the Complexity of Immune-Cancer Cell Interactions: Empowering the Future of Cancer Immunotherapy. Cancers (Basel). 2023 Aug 21;15(16):4188. doi: 10.3390/cancers15164188.
PMID: 37627216; PMCID: PMC10453128.